Drug Search Results
More Filters [+]

SLV-337

Alternative Names: slv-337, slv337, slv 337
Latest Update: 2012-01-04
Latest Update Note: Clinical Trial Update

Product Description

For Type 2 Diabetes

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SLV-337

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 2 Diabetes

Phase 1: General Diabetes|Healthy Volunteers|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2009-011589-27

P2

Completed

Type 2 Diabetes

2010-12-02

S337.2.001

P2

Completed

Type 2 Diabetes

2010-12-01

S337.1.005

P1

Completed

General Diabetes|Healthy Volunteers

2010-10-01

S337.1.002

P1

Completed

Type 2 Diabetes

2009-07-01

Recent News Events

Date

Type

Title